George P. Vlasuk, Ph.D., joined Sirtris in early 2009 and serves as Chief Executive Officer. In this role, Dr. Vlasuk's leadership responsibilities include all research, development, and operations at Sirtris, which is focused on discovering and developing small molecule drugs to treat diseases of aging.

Dr. Vlasuk has led numerous R&D efforts in both biotechnology and pharmaceutical companies throughout his career. Prior to joining Sirtris, Dr. Vlasuk served as Vice President of Metabolic Disease and Hemophilia Research at Wyeth, where he led teams focused on developing new therapeutic approaches for Type 2 Diabetes, obesity, diabetic complications, hemophilia, heart failure, dyslipidemia/atherosclerosis and cardiac arrhythmia. Prior to joining Wyeth in 2003, Dr. Vlasuk spent 12 years at Corvas International (now Dendreon) where he was Chief Scientific Officer and a member of the Board of Directors. Dr Vlasuk also spent seven years at Merck and two years at California Biotechnology Inc. (now Scios).

Dr. Vlasuk holds a B.S. in Clinical Chemistry, a Ph.D. in Chemistry/Biochemistry, and did postdoctoral work in Molecular Biology. He has published over 100 peer-reviewed articles, book chapters and reviews, and is an inventor on 38 issued U.S. and foreign patents.

Eric Jacobson, M.D., joined Sirtris in 2009 as Chief Medical Officer. In this role, Dr. Jacobson oversees all clinical and regulatory activities and the development of Sirtris’ drug candidates. Dr. Jacobson's professional career spans 20 years and encompasses private practice, academic and industrial positions. Prior to joining Sirtris, Dr. Jacobson held the position of SVP, Clinical Research & Regulatory Affairs and Chief Medical Officer at Synta Pharmaceuticals. While at Synta, Dr. Jacobson oversaw all aspects of Clinical Development including the Medical Research, Medical Affairs, Regulatory Affairs, Q/A, Pharmacology, and Pharmacovigilance Departments. Prior to that Dr. Jacobson was Senior Director, Clinical Research at Millennium Pharmaceuticals where he participated in creating development strategies for various small-molecule and biotherapeutic compounds targeting rheumatoid arthritis, multiple sclerosis, chronic hepatitis C, and HIV. Dr. Jacobson served as U.S. Medical Director of New Clinical Therapies at Serono Laboratories, Inc., where he directed a clinical research team supporting multinational registration of new products and expanded indications of existing products, and was an academic rheumatologist at the University of Massachusetts Medical Center. Dr. Jacobson was selected for “The Best Doctors in America” a number of times, including every year since 2000, and he has served as a reviewer for the Journal of the American Medical Association. Dr. Jacobson earned his M.D. from Rush Medical College of Rush University in Chicago, Illinois, and his B.S. at the University of Illinois at Champaign-Urbana.